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Self-reactive T cells that escape thymic negative 
selection are kept in check by peripheral toler-
ance mechanisms that include T cell anergy and 
deletion. Research into how self-reactive T cells 
are tolerized in LNs has focused largely on 
DCs. Depending on their functional status, 
antigen presentation by DCs can indeed lead 
to different forms of T cell tolerance (Steinman 
et al., 2003; Helft et al., 2010). Recently, how-
ever, LN-resident radio-resistant cells, the LN 
stromal cells (LNSCs), have been suggested to 
contribute to peripheral T cell tolerance. These 
cells can be discriminated based on their lack of 
CD45 expression and the differential expres-
sion of podoplanin (gp38) and PECAM (CD31). 
Fibroblastic reticular cells (FRCs, gp38+CD31) 
produce chemokines such as CCL19 and CCL21, 
thereby providing a scaffold on which the CC-
chemokine receptor 7 (CCR7)+ T cells and 
DCs can migrate and establish contact (Turley 
et al., 2010). In LNs, blood endothelial cells 
(BECs, gp38CD31+) lining the high endothe-
lial venules are crucial for lymphocyte entry 
(Mueller and Germain, 2009). Afferent lym-
phatic endothelial cells (LECs, gp38+CD31+) 
promote DC entry (Johnson et al., 2006; Acton 
et al., 2012), as well as antigen delivery (Sixt 
et al., 2005; Roozendaal et al., 2009), into LNs, 
whereas efferent LECs regulate T cell egress 
from LNs (Cyster and Schwab, 2012). The 
function of so-called double-negative (DN) 
stromal cells (gp38CD31) remains unknown. 
For many years, LNSCs were thought to only 
play an architectural role in LN construction 
and homeostasis. More recently, however, stud-
ies have identified LNSCs as active players in 
modulating adaptive immune responses (Swartz 
and Lund, 2012). In vitro, DC adhesion to LECs 
leads to decreased levels of co-stimulatory 
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Dendritic cells (DCs), and more recently lymph node stromal cells (LNSCs), have been de-
scribed to tolerize self-reactive CD8+ T cells in LNs. Although LNSCs express MHCII, it is 
unknown whether they can also impact CD4+ T cell functions. We show that the promoter IV 
(pIV) of class II transactivator (CIITA), the master regulator of MHCII expression, controls 
endogenous MHCII expression by LNSCs. Unexpectedly, LNSCs also acquire peptide–MHCII 
complexes from DCs and induce CD4+ T cell dysfunction by presenting transferred complexes 
to naive CD4+ T cells and preventing their proliferation and survival. Our data reveals a 
novel, alternative mechanism where LN-resident stromal cells tolerize CD4+ T cells through 
the presentation of self-antigens via transferred peptide–MHCII complexes of DC origin.
© 2014 Dubrot et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
on May 1, 2019jem.rupress.org Downloaded from 
http://doi.org/10.1084/jem.20132000Published Online: 19 May, 2014 | Supp Info: 
1154 LNSCs and CD4+ T cell tolerance | Dubrot et al.
et al., 2012), LECs, BECs, and FRCs, but not DN cells (Fig. S1), 
expressed low basal levels of MHCII molecules (Fig. 1 A). 
MHCII expression is almost exclusively controlled by a single 
master regulatory factor, CIITA (Reith et al., 2005). Expres-
sion of CIITA is regulated mainly at the transcriptional level 
by a large regulatory region that contains three distinct pro-
moters in mice, pI, pIII, and pIV (Fig. S2; Reith et al., 2005). 
We quantified pI, pIII, and pIV mRNA in FACS-sorted 
FRCs, BECs, and LECs from CD45neg-enriched LN frac-
tions. Although pI and pIII mRNAs were undetectable, all 
three LNSC subpopulations expressed pIV mRNA (Fig. 1 B). 
Because pIV is induced by IFN-, we injected WT and pIV 
knockout (pIV/) mice with IFN- and observed that 
LECs, BECs, and FRCs isolated from WT mice strongly up-
regulated MHCII compared with untreated WT mice (Fig. 1 C). 
In contrast, LECs, BECs and FRCs isolated from pIV/ 
mice did not increase MHCII after IFN- treatment (Fig. 1 C), 
demonstrating that IFN-–mediated MHCII up-regulation 
by LNSC is pIV dependent. Surprisingly, although only pIV 
mRNA was detected in LNSC (Fig. 1 B), basal MHCII ex-
pression was slightly reduced but not abrogated in cells iso-
lated from untreated pIV/ mice. Similarly, this reduced but 
clear expression of MHCII was detectable in IFN-R/ 
LNSCs (Fig. 1 D), indicating that although steady-state IFN- 
is partially responsible for pIV-dependent basal MHCII ex-
pression, other mechanisms driving MHCII expression must 
also exist.
CIITA-independent MHCII expression is an event that 
only exists rarely (Arancibia-Cárcamo et al., 2004; Zinzow-
Kramer et al., 2012). LNSCs isolated from mice deficient for 
the full CIITA gene (CIITA/ mice) were, however, found 
negative for MHCII expression (Fig. 1 E), ruling out a CIITA-
independent MHCII expression by LNSCs. Even though no 
other CIITA promoter activity was detected except for pIV 
(Fig. 1 B), we nevertheless checked for MHCII expression 
by LNSCs isolated from mice deficient for pI (pI/), and 
double deficient for pIII and pIV (pIII+IV/). Whereas 
pIII+IV/ LNSCs express similar levels of MHCII com-
pared with pIV/ LNSCs, MHCII expression was dramati-
cally and significantly reduced in LECs, BECs, and FRCs 
from pI/ mice (Fig. 1 E). This result was unexpected be-
cause pI has been shown to control CIITA expression only in 
conventional DCs, macrophages, and microglial cells (Reith 
et al., 2005).
LNSCs acquire MHCII from hematopoietic cells
Even though pI mRNA was undetectable in WT LNSCs, 
pI/ LNSCs exhibited a dramatic decrease in MHCII ex-
pression. We hypothesized that although LNSCs endogenously 
up-regulated MHCII molecules in an IFN-–inducible 
pIV-dependent manner (Fig. 1 C), they may also acquire 
MHCII from hematopoietic cells under steady state. Accord-
ingly, MHCII expression by macrophages and DCs was not 
totally abrogated in pI/ mice (Fig. 2 A) and may explain the 
remaining low MHCII expression by pI/ LNSCs (Fig. 1 E). 
An alternative explanation is that pI/ mice are pIV sufficient, 
molecules by DCs (Podgrabinska et al., 2009). Furthermore, 
FRCs inhibit the proliferation of newly activated T cells 
through a NOS2-dependent mechanism, but also indirectly 
affect T cell proliferation by suppressing DC functions (Khan 
et al., 2011; Lukacs-Kornek et al., 2011; Siegert et al., 2011). 
In addition, FRCs can suppress acute T cell proliferation both 
in vitro and in vivo (Siegert et al., 2011). Other studies have 
convincingly demonstrated a role for LNSCs in maintaining 
peripheral CD8+ T cell tolerance via direct presentation of 
self-antigens to self-reactive CD8+ T cells. Unlike DCs, which 
acquire antigens and subsequently cross-present self-peptides 
to CD8+ T cells in the draining LNs, LNSCs ectopically ex-
press and present PTAs (peripheral tissue antigens) to CD8+ 
T cells, and consequently induce clonal deletion of self-reactive 
CD8+ T cells (Lee et al., 2007; Nichols et al., 2007; Gardner 
et al., 2008; Magnusson et al., 2008; Yip et al., 2009; Cohen 
et al., 2010; Fletcher et al., 2010). In addition, we have re-
cently shown that tumor-associated LECs can scavenge tumor 
antigens and cross-present them to cognate CD8+ T cells, 
driving their dysfunctional activation (Lund et al., 2012). The 
lack of expression of co-stimulatory molecules such as CD80/86, 
and high PD-L1 expression levels at the surface of LECs 
(Fletcher et al., 2010; Tewalt et al., 2012), were proposed as the 
major mechanisms by which these cells induce deletional 
CD8+ T cell tolerance.
While accumulating evidence suggests that direct antigen 
presentation by LNSCs promotes CD8+ T cell deletion, it is 
unknown whether LNSCs can similarly contribute to CD4+ 
T cell tolerance. As previously described, FRCs, BECs, and 
LECs express MHCII under virally induced inflammatory 
conditions or IFN- treatment (Malhotra et al., 2012; Ng 
et al., 2012). However, little is known about the regulation of 
MHCII expression by LNSCs.
Here, we show that endogenous MHCII expression by 
LNSCs is controlled by the IFN-–inducible promoter IV 
(pIV) of class II transactivator (CIITA). Due to basal pIV activ-
ity, LNSCs express low levels of MHCII upon steady state and 
up-regulate these molecules when exposed to IFN-. Un-
expectedly, in addition to low endogenous basal expression, the 
majority of MHCII molecules detected at LEC, BEC, and 
FRC surface were acquired from DCs. Furthermore, antigen-
presenting DCs transfer antigenic peptide–MHCII (pMHCII) 
complexes to LNSCs, in a process dependent on both cell–
cell contact and DC-derived exosomes. Importantly, acquired 
pMHCII complexes were presented by LECs, BECs, and 
FRCs to CD4+ T cells and promoted cognate CD4+ T cell 
dysfunction by impairing their survival and response to fur-
ther restimulation. These data suggest that LNSCs serve more 
diverse roles than previously thought in regulating CD4+  
T cell immunity.
RESULTS
CIITA pIV drives IFN-–mediated MHCII up-regulation, but 
not basal MHCII expression, by LECs, BECs, and FRCs
We first characterized steady-state MHCII expression by pri-
mary murine LNSCs. As previously described (Malhotra 
JEM Vol. 211, No. 6 1155
Article
Figure 1. CIITA pIV controls IFN-–mediated up-regulation, but not steady-state expression of MHCII by LNSCs. (A) LNSCs were defined by FACS 
as follows: LEC, CD45 CD31+ gp38+; BEC, CD45 CD31+ gp38; FRC, CD45 CD31 gp38+; DN, CD45 CD31 gp38. Histograms show MHCII expression 
levels by each LNSC population (gray histograms, isotype control). Data are representative of 4 independent experiments with at least 3 mice each. (B) Ciita 
promoters pI, pIII, and pIV mRNA levels were quantified by qPCR from FACS-sorted LEC, BEC, or FRC. Indicated control cells (gray bars) were used as reference. 
Data are representative of 3 independent experiments, with a pool of 10 mice each. (C) Mice were injected subcutaneously (green) or not (blue) with IFN- 
and draining LNs were collected 24 h later. Histograms show MHCII expression levels on LEC, BEC, and FRC. Graphs depict MHCII MFI where each symbol 
represents individual mouse. Data are representative of 3 independent experiments, with 4 mice per group. ***, P < 0.001, n.s. = not significant. Error bars 
depict mean ± SEM. (D and E) Histograms show MHCII expression levels on LEC, BEC, and FRC from indicated mice. Histograms are representative of at least  
2 independent experiments with 2–3 mice per group. (E) Graphs depict MHCII MFI where each symbol represents individual mouse. Data are pooled from  
3 independent experiments with 2–3 mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s. = not significant. Error bars depict mean ± SEM.
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Consistently, MHCII expression by LNSCs from WT BM: 
MHCII/ chimeric mice was restored to similar levels com-
pared with pIV/ LNSCs, demonstrating that steady-state 
MHCII at LNSC surfaces were acquired from hematopoietic 
cells (Fig. 2 B). An almost total lack of MHCII expression by 
LNSCs from MHCII/ BM: pIV/ chimeric mice was ob-
served (Fig. 2 B), suggesting that LNSCs do acquire MHCII 
from hematopoietic cells. In addition, we reconstituted ir-
radiated MHCII/ recipient mice with a mixture (1:1) of 
WT and I-Ab GFP+ BM cells. Levels of GFP expression by 
MHCII+ LECs, BECs, and FRCs were intermediate in mixed 
and as mentioned previously, low levels of IFN- in vivo 
promote slight endogenous MHCII expression by LNSCs 
(Fig. 1 D). The hypothesis of MHCII acquisition by LNSCs 
from hematopoietic cells was tested by generating BM chi-
meric mice in which only the hematopoietic cell compart-
ment or, conversely, the radioresistant stromal cells originate 
from WT. As mentioned above (Fig. 1), control pIV/ LNSCs 
exhibited a reduced but significant MHCII expression com-
pared with WT LNSCs (Fig. 2 B). Because there is no endog-
enous MHCII expression in pIV/ LNSCs, we considered 
that this expression reflects only acquired MHCII molecules. 
Figure 2. LNSCs acquire MHCII mol-
ecules from hematopoietic cells. (A) MHCII 
MFI on splenic macrophages and BMDCs from 
WT, pI/, and CIITA/ mice. Error bars indi-
cate mean + SEM. Data are representative of 
4 independent experiments, with 2–3 mice 
per group. *, P < 0.05; ***, P < 0.001. (B) MHCII 
MFI on LEC, BEC, and FRC from indicated con-
trol mice and WT:MHCII/ or MHCII/:
pIV/ BM chimeric mice which were gener-
ated as described in Materials and methods. 
Graphs are representative of 3 independent 
experiments with 5 mice per group. ***, P < 
0.001. Error bars depict mean ± SEM. (C) His-
tograms show GFP expression gated on  
MHCII+ LEC, BEC, and FRC from indicated BM 
chimeric mice generated in MHCII/ recipi-
ents. Graphs are representative of 2 indepen-
dent experiments, with 3–4 mice per group.  
*, P < 0.05; **, P < 0.01. Error bars depict 
mean ± SEM. (D) Mice were either sublethally 
irradiated or untreated, and LNs harvested 3 d 
later. Data show MHCII MFI on LEC, BEC, and 
FRC and are representative of 2 independent 
experiments, with 7 mice per group. Each sym-
bol represents an individual mouse. *, P < 0.05;  
**, P < 0.01; ***, P < 0.001. Error bars depict 
mean ± SEM. (E) LN cells were cultured and 
nonadherent hematopoietic cells were re-
moved daily. LEC and FRC were analyzed at 
indicated times for MHCII expression. Data are 
representative of at least 3 independent ex-
periments with minimum 3 mice per group.
JEM Vol. 211, No. 6 1157
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DCs transfer MHCII to LNSCs in vitro
We next investigated which cell types are involved in the 
transfer of MHCII molecules to LNSCs. MHCII-negative 
LECs and FRCs (Fig. 3 A) were co-cultured for 24 h with 
MHCII+ cells, namely macrophages, B cells, or LPS-treated 
DCs. We observed that only DCs were capable of transferring 
MHCII to LNSCs (Fig. 3 A). In vivo experiments further 
suggested that this transfer is exclusively mediated by DCs. 
First, MHCII expression by pIII+IV/ LNSCs was compa-
rable to pIV/ LNSCs (Fig. 1 E), demonstrating that B cells, 
which rely on pIII, are not involved in this process. Second, 
MHCII expression by LNSCs was not reduced after deple-
tion of macrophages using clodronate liposomes (unpublished 
data). Only WT and not MHCII/ DCs transferred MHCII 
to both WT and MHCII/ LNSC, ruling out the possibility 
that DC-derived soluble inflammatory mediators induce en-
dogenous MHCII up-regulation by LNSCs (Fig. 3 B). Fur-
thermore, MHCII transfer from DCs to LECs and FRCs was 
detectable within 2 h of co-culture and increased over time 
(Fig. 3 C). Finally, we investigated whether MHCII transfer 
to LECs and FRCs was different depending on DC activa-
tion state. Both untreated DCs (immature DCs [iDCs]) and 
LPS-treated DCs (mature DCs [mDCs]) transferred MHCII 
to LNSCs. LNSCs co-cultured with mDC acquired more 
MHCII compared with those incubated with iDC (Fig. 3 D). 
Interestingly, DCs cultured for 24 h with LEC/FRC cultures 
BM chimeras compared with control MHCII/ recipient 
mice reconstituted with exclusively WT or I-Ab GFP+ BM 
cells (Fig. 2 C). Thus, LNSCs from mixed BM chimeric mice 
express both nonfluorescent (from WT BM) and GFP+ (from 
I-Ab GFP+ BM) MHCII molecules, reinforcing the idea that 
nonhematopoietic radioresistant LECs, BECs, and FRCs ac-
quire MHCII from hematopoietic cells. To further test our 
hypothesis, we sublethally irradiated WT mice to eliminate 
hematopoietic cells. pIV/ mice were included to avoid any 
possible endogenous MHCII up-regulation after irradiation-
induced inflammation. 3 d after irradiation, the number of 
hematopoietic cells in LN was dramatically reduced (not de-
picted) and correlated with a significant decrease in MHCII 
expression by both WT and pIV/ LNSCs (Fig. 2 D). These 
results indicated that LNSCs transiently acquire MHCII 
molecules from hematopoietic cells in vivo. To analyze this 
phenomenon in vitro, we generated LEC/FRC cultures 
(Lukacs-Kornek et al., 2011). In brief, LN cells were cultured 
for 5–7 d and washed daily to remove nonadherent hema-
topoietic cells. Consistent with our hypothesis that LNSCs 
acquire most MHCII from hematopoietic cells in steady state, 
removal of hematopoietic cells correlated with the disappear-
ance of MHCII expression levels on LECs and FRCs over 
time (Fig. 2 E). This also reinforced our in vivo results show-
ing that transferred MHCII are not stable at the surface of 
LNSC (Fig. 2 D).
Figure 3. DCs transfer MHCII molecules to  
LNSCs in vitro. (A) LECs/FRCs from WT mice were 
co-cultured alone (gray) or in the presence of macro-
phages (blue), B cells (green), or DCs (red) for 24 h.  
(B) WT or MHCII/ LECs/FRCs were co-cultured  
for 24 h in the presence or absence of DCs from ei-
ther WT or MHCII/ mice, as indicated. (C) LECs/FRCs 
from WT mice were co-cultured alone (gray) or in the 
presence of DCs for 2 h (blue), 6 h (green), or 24 h 
(red). (D) LECs/FRCs from WT mice were co-cultured 
alone (gray) or in the presence of DCs pretreated (red) 
or not (blue) with LPS for 24 h. (A–D) Histograms 
show MHCII levels on LEC (left) and FRC (right). Data 
are representative of at least 2 independent experi-
ments with minimum 3 mice per group. (E) MHCII 
expression by LPS-treated DCs cultured with either 
LEC/FRC (red) or in the presence of LEC/FRC culture 
supernatant (Sup., green) for 24 h. Data representa-
tive of 3 independent experiments with 3 mice per 
group. (F) LECs/FRCs from WT mice were co-cultured 
alone or with indicated sorted LN DC subsets for  
24 h. Graphs show MHCII MFI on LEC and FRC and are 
representative of 2 independent experiments. Each 
experiment is a pool of 10 mice. Error bars depict 
mean ± SEM.
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model of contact hypersensitivity (CH) to enhance migration 
of skin DCs to draining LNs (Fig. 4 C; Thomas et al., 2012). 
To avoid endogenous MHCII up-regulation by LNSCs due 
to skin inflammation and thereby quantify only DC transfer–
mediated MHCII expression, CH was induced in pIV/ 
mice. Expression of MHCII was significantly increased at 24 
and 48 h in LEC and BEC populations and at 48 h in FRCs 
after CH (Fig. 4 D). Altogether, our data demonstrated that 
LNSCs acquire MHCII molecules from DCs in vivo and that 
the intensity of MHCII expression by LNSCs proportionally 
correlates with the numbers of DCs in LNs.
Mechanisms of MHCII transfer from DCs to LNSCs
To investigate whether MHCII transfer from DCs to LNSCs 
relies on active processes, isolated LN LEC/FRC cultures 
were co-cultured with paraformaldehyde (PFA)-pretreated 
DCs. These paralyzed DCs entirely lost their ability to transfer 
expressed lower MHCII compared with DCs cultured alone 
(Fig. 3 E), consistent with MHCII transfer from DCs to LNSCs. 
Importantly, we observed that different ex vivo purified 
DC subsets from steady-state LN (Fig. S3) transferred MHCII 
to MHCII-deficient LECs and FRCs (Fig. 3 F), with an ef-
ficacy that correlated with the DCs’ own MHCII expres-
sion (Fig. S3).
DCs transfer MHCII to LNSCs in vivo
To definitively demonstrate that LNSCs acquire MHCII 
molecules from DCs in vivo, we manipulated the numbers of 
DCs in LNs and analyzed the impact on MHCII expression 
by LNSCs. First, K14-VEGFR3-Ig transgenic mice (Mäkinen 
et al., 2001) that are deficient in skin-afferent lymphatics, re-
sulting in an abrogation of skin DC homing to LN (Fig. 4 A), 
exhibited reduced MHCII expression in LECs, BECs, and 
FRCs compared with WT cells (Fig. 4 B). Next, we used a 
Figure 4. DCs transfer of MHCII molecules to LNSCs in vivo. (A and B) Frequencies of resident (CD11chiMHCIIint) and migratory (CD11intMHCIIhi) DC 
populations (A), and MHCII expression on LNSCs (B), in LN from WT and K14-VEGFR3-Ig (TG) mice. Graphs show MHCII MFI on LEC, BEC, and FRC from WT 
and TG mice. Each symbol represents an individual mouse. (C and D) A 1:1 acetone-butyl phthalate mixture was applied or not in the skin of pIV/ mice. 
Frequencies of resident and migratory DC populations in the draining LNs 1 d after CH (C). MHC-II levels in LEC, BEC, and FRC 0, 24, and 48 h after CH (D). 
Graphs show MHCII MFI on LEC, BEC, and FRC. (A–D) Data are representative of at least 2 independent experiments with minimum 3 mice per group.  
*, P < 0.05; **, P < 0.01. Error bars depict mean ± SEM.
JEM Vol. 211, No. 6 1159
Article
on these cells (Fig. 5 B), suggesting that DC-derived vesicles 
might also be involved in transferring MHCII molecules 
in vitro. Indeed, DC-derived exosomes have been previously 
described to mediate intercellular transfer of surface proteins 
(Davis, 2007). To determine whether exosomes were involved 
in the process of MHCII transfer from DCs to LNSCs, we 
isolated and purified exosomes from cultured DCs as previously 
MHCII to LECs and FRCs (Fig. 5 A), suggesting an active 
transfer of MHCII from donor to recipient cells. To investi-
gate whether this process was cell–cell contact dependent, we 
co-cultured DCs and LEC/FRCs in different compartments 
separated by a culture insert membrane, and observed a dra-
matic reduction of MHCII expression on LECs and FRCs 
(Fig. 5 B). However, small amounts of MHCII were detectable 
Figure 5. Mechanisms of MHCII transfer. 
(A) LECs/FRCs were co-cultured overnight 
with BMDCs previously treated (DC) or not 
with PFA (PFA DC). Histograms show MHCII 
levels on LEC and FRC. Data are representative 
of 3 independent experiments. (B) LECs/FRCs 
were co-cultured overnight with BMDCs in 
the same compartment or in two compart-
ments separated by a transwell (TW) mem-
brane. Histograms show MHCII levels on LEC 
and FRC. Graphs show MHCII MFI on LEC (left) 
and FRC (right). Data are representative of 3 
independent experiments. Error bars depict 
mean ± SEM. Each symbol represents experi-
mental replicates. (C) Expression of MHCII, 
CD80, CD86, and CD40 by DC-derived exo-
somes. Histograms are representative of 2 
independent experiments. (D) 5 × 104 LECs/
FRCs were co-cultured overnight with 5 × 104 
(1:1) LPS-treated BMDCs or exosomes purified 
from 106 (1:20), 2 × 106 (1:40), or 3 × 106 
(1:60) LPS-treated BMDCs. Data show MHCII 
MFI on LEC and FRC and are representative of 
2 independent experiments. *, P < 0.05; **, P < 
0.01; ***, P < 0.001; n.s. = not significant. 
Error bars depict mean ± SEM. Each symbol 
represents experimental replicates. (E) Levels 
of CD80, CD86, CD40, and CD11c expression 
by LEC and FRC cultured alone or co-cultured 
overnight with LPS-treated BMDCs. Red his-
tograms represent expression of indicated 
molecules by LEC and FRC compared with 
isotype (gray histograms). Dotted histograms 
represent expression of the molecules by  
BMDCs. Data are representative of 3 indepen-
dent experiments. (F) Expression of CD80, 
CD86, CD40, and CD11c by LEC, BEC, and FRC 
isolated from LN (red histograms) compared 
with isotype (gray histograms). Histograms 
are representative of 2 independent experi-
ments with 2–4 mice per group.
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by LECs and FRCs were loaded with free FITC+ OVA pep-
tide (Fig. 6 B). Consistent with a possible role for exosomes in 
the transfer of pMHCII to LNSCs, exosomes derived from 
FITC-labeled OVA323-339-loaded DCs were FITC+ (Fig. 6 C). 
Importantly, all FITC+ exosomes were MHCII positive, rein-
forcing the idea that exosomes might transfer pMHCII com-
plexes rather than free peptide (Fig. 6 C).
To study the impact of pMHCII transfer from DCs 
to LNSCs on CD4+ T cells in vivo, we took advantage of 
the mouse model CD11cDOG (CD11cDTR-OVA-eGFP) 
in which OVA protein is exclusively expressed by DCs 
(Hochweller et al., 2008; Fig. 7 A). In contrast to DCs, LNSCs 
purified from CD11cDOG mice did not express OVA mRNA 
(Fig. 7 B), excluding the possibility that in this model, LNSCs 
endogenously express and may directly present OVA to 
T cells. Next, LNSCs and DCs were sorted from either WT 
or CD11cDOG mice and incubated for 3 d with CFSE- 
labeled OT-II CD4+ T cells. As expected, T cells proliferated 
well after culture with CD11cDOG but not WT DCs (Fig. 7 C). 
Although we did not observe any significant proliferation 
when OT-II cells were incubated with WT or CD11cDOG 
LECs, BECs, or FRCs, Annexin V staining revealed that more 
T cells became apoptotic when co-cultured with CD11cDOG 
LECs compared with WT LECs (Fig. 7 C). Thus, consistent 
with published studies showing that LECs can induce T cell 
deletion (Lund et al., 2012; Tewalt et al., 2012) and correlating 
with the higher expression of PD-L1 by LECs compared 
with other LNSC populations observed (Fig. 7 D), our data 
suggest that under steady state, LECs acquire pMHCII com-
plexes from DCs and promote CD4+ T cell apoptosis in an 
antigen-specific manner.
described (Théry et al., 2002). We found that DC-derived 
exosomes were positive for MHCII expression (Fig. 5 C). 
When DC-derived exosomes were added to LEC/FRC cul-
tures, MHCII expression increased in a dose-dependent man-
ner on both LECs and FRCs (Fig. 5 D), but to a lesser extent 
compared with DCs (Fig. 5 D).
Strikingly, in vitro cultured LECs and FRCs did not ex-
press co-stimulatory molecules, nor did they acquire them 
when co-cultured with DCs (Fig. 5 E). Accordingly, DC- 
derived exosomes were negative for co-stimulatory molecules 
(Fig. 5 C). Furthermore, ex vivo LNSCs were negative for the 
CD11c marker and expressed low levels of co-stimulatory 
molecules (Fig. 5 F). Altogether, these results suggest that the 
process of transfer from DCs to LNSCs is restricted to MHCII 
molecules and that DCs transfer MHCII to LNSCs in a mainly 
cell contact–dependent manner, although other mechanisms, 
including DC-derived exosomes, might also play a role.
LNSCs present pMHCII acquired from DCs  
and induce CD4+ T cell tolerance
Next, we asked whether peptide-loaded MHCII molecules 
(pMHCII) could also be transferred from DCs to LNSCs, and 
if so, whether these transferred complexes could be function-
ally presented to CD4+ T cells. To this end, we first loaded 
DCs with FITC-labeled OVA323-339 peptide and, after thor-
ough washing, co-cultured them with LEC/FRCs. We found 
efficient transfer of FITC fluorescence to both LECs and 
FRCs (Fig. 6 A), suggesting that DCs can transfer pMHCII 
complexes to LNSCs in vitro. Importantly, similar results 
were obtained using CIITA/ LEC/FRC cells, ruling out 
the possibility that endogenous MHCII molecules expressed 
Figure 6. DCs transfer pMHCII complexes to LEC and FRC 
in vitro. (A and B) WT (A) and CIITA/ (B) LEC/FRC were co-
cultured with BM-DCs preloaded with OVA323-339 (red histo-
grams) or FITC-labeled OVA323-339 (green histograms). After 24 h, 
FITC signals was analyzed by FACS in LECs and FRCs and com-
pared with isotype control (gray histogram). Graphs show FITC 
MFI and are representative of 3 independent experiments. Error 
bars depict mean ± SEM. ***, P < 0.001. (C) Exosomes were puri-
fied from supernatant of 5 × 106 BMDCs loaded with FITC- 
labeled (green) or unlabeled (red) OVA peptide (1 µM). DC-derived 
exosomes were coupled with latex beads and analyzed by FACS 
for FITC fluorescence (left) and for MHCII expression (compared 
with isotype control in gray) after gating on FITC+ exosomes 
(right). Data representative of 3 independent experiments.
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to CD11cDOG LECs, BECs, and FRCs was further reduced 
compared with T cells preexposed to WT LECs, BECs, and 
FRCs (Fig. 8 A). We did not observe any differences in T reg 
cell frequency, whether T cells were precultured alone or with 
LNSNs derived from WT or CD11cDOG mice (unpublished 
data). To firmly demonstrate that pMHCII complexes are 
transferred from DCs to LNSC in vivo, and to rule out that 
free OVA released from CD11cDOG DCs is captured and 
presented via endogenous MHCII expressed at the surface 
of LNSCs, experiments were repeated using BM chimeric 
mice in which LNSCs do not express endogenous MHCII. 
CD11cDOG BM cells were used to reconstitute irradiated 
CIITA/ recipient mice. Using this setting, we confirmed 
that LECs, BECs, and FRCs isolated from CD11cDOG:
To further investigate the inhibitory capacity of LNSCs, 
T cells were harvested and restimulated using anti-CD3/CD28 
antibodies after 3 d of culture. OT-II cells that were not ex-
posed to any other cells noticeably proliferated upon CD3/
CD28 stimulation (Fig. 8 A), as observed for T cells exposed 
for 3 d to WT DCs. However, OT-II cells exposed to WT 
LECs responded less efficiently to restimulation compared 
with unexposed T cells, confirming that LNSCs suppress 
T cell proliferation independently of the presentation of 
pMHC complexes (Khan et al., 2011; Lukacs-Kornek et al., 
2011; Siegert et al., 2011). Ex vivo, LECs appeared to be 
more efficient compared with BECs and FRCs at inhibiting 
T cell proliferation independently of antigen presentation 
(Fig. 8 A). Importantly, the proliferation of T cells preexposed 
Figure 7. LECs presenting pMHCII acquired from DCs promote T cell apoptosis. (A) A schematic view of the protocol used to test the transfer of 
pMHCII (OVAp-MHCII) from DCs to LNSCs in CD11cDOG mice and its impact on OVA-specific CD4+ T cell (OTII) outcome. LNSCs were purified from 
CD11cDOG mice (in which OVA is selectively expressed in DCs) and co-cultured with OTII cells. (B) OVA mRNA levels were quantified by qPCR from FACS-
sorted B cells, DCs, LECs, BECs, or FRCs of CD11cDOG mice. Data are representative of 2 independent experiments with a pool of 7 to 12 mice each.  
(C) LNSCs and DCs were purified from CD11cDOG or WT mice, and ex-vivo cultured with TCR transgenic CD45.1 CD4+ T cells (OTII). (C) CFSE and Annexin V 
profiles of OTII cells, gated on CD4+ and CD45.1+ cells after 3 d of culture with indicated cells. Dot plots are representative of 3 independent experiments 
with 16 mice per group. (D) Histograms show PD-L1 expression by LECs, BECs, and FRCs compared with isotype control (gray). Graphs represent PDL-1 MFI 
for each cell subset and are representative of 3 independent experiments with 3 mice. Error bars depict mean ± SEM.
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Our data provide ample evidence that low endogenous 
MHCII expression by LNSCs is driven by basal pIV activity, 
whereas the majority of MHCII molecules are acquired from 
DCs. First, LECs/FRCs cultured in vitro do not express 
MHCII but acquire these molecules after co-culture with 
DCs, but not B cells or macrophages. Furthermore, changes 
in DC numbers in LN in vivo proportionally modulate 
MHCII expression levels by LNSCs. First, a decrease in DC 
numbers caused by sublethal mouse irradiation significantly 
reduces MHCII expression by LNSCs. This process mainly 
eliminates resident DCs, and not some of the radioresistant 
migratory DC subsets such as Langerhans cells and dermal 
DCs, suggesting that LN-resident DCs contribute to MHCII 
transfer to LNSCs. In contrast, preventing skin-resident DC 
trafficking to LNs dramatically decreases surface MHCII ex-
pression levels on LNSCs. Interestingly, although significantly 
reduced, MHCII molecules can still be detected at the surface 
of LNSC, suggesting that both migrating and LN-resident 
DCs transfer MHCII molecules to LNSCs. Conversely, pro-
moting skin DC migration to LN using the CH model in-
creases MHCII expression by LNSCs. This result was obtained 
in pIV/ mice, in which LNSCs cannot endogenously ex-
press MHCII molecules, demonstrating that increased DC 
numbers enhance the process of MHCII transfer to LNSCs. 
Interestingly, both steady-state and activated DCs, as well as 
different DC populations purified from LN, can transfer MHCII 
to LNSC, showing that this process is not restricted to specific 
DC activation states or subsets. Rather, the amount of MHCII 
transferred seems to be dependent on the level of expression 
of those molecules by DCs.
Evidence that DCs can transfer pMHCII complexes at 
the surface of LNSCs was provided in vitro using a fluores-
cent peptide and also in vivo using mice in which only DCs 
CIITA/ mice inhibit T cell proliferation in an antigen-
specific manner compared with LNSCs isolated from WT:
WT mice (Fig. 8 B). Altogether, our data demonstrated that 
LNSCs acquired OVA323-339–MHCII complexes from DCs 
in vivo, and induced an antigen-specific inhibition of OT-II 
survival and proliferation.
DISCUSSION
Emerging evidence suggests that stromal cells in LNs play an 
important role in the regulation of peripheral immune re-
sponses (Bajénoff et al., 2006; Mueller and Germain, 2009). 
Many current studies have focused on dissecting the complex 
mechanisms responsible for LNSC immunoregulation. Par-
ticular LNSC subsets, mainly LECs and FRCs, suppress acti-
vated CD4+ and CD8+ T cell proliferation independently on 
the presentation of pMHC complexes (Khan et al., 2011; 
Lukacs-Kornek et al., 2011; Siegert et al., 2011). LNSCs also 
express various PTAs and contribute to the maintenance of 
deletional peripheral CD8+ T cell tolerance (Lee et al., 2007; 
Nichols et al., 2007; Magnusson et al., 2008; Cohen et al., 
2010; Fletcher et al., 2010; Tewalt et al., 2012). However, 
whether the different LNSC subpopulations influence CD4+ 
T cell tolerance is still unclear. LECs, BECs, and FRCs have 
been shown to express low surface MHCII levels in steady-
state and to increase expression upon inflammation (Malhotra 
et al., 2012). Our study clarifies the mechanisms accounting 
for the regulation of MHCII expression by LNSCs. We show 
that LECs, BECs, and FRCs, but not DN cells, express MHCII 
in steady state and up-regulate surface MHCII upon expo-
sure to IFN-. We further demonstrated that LNSCs exclu-
sively express pIV of CIITA, and that IFN-–mediated MHCII 
expression is pIV-dependent.
Figure 8. T cells preexposed to LNSCs present-
ing acquired pMHCII failed to proliferate upon 
restimulation. (A) OTII+ cells were harvested after 3 d of 
exposure to indicated cells from either CD11cDOG or WT 
mice (as in Fig. 7 C) and restimulated with anti-CD3/anti-
CD28 for 3 additional d. Proliferation (percentage) of 
gated CD45.1+ CD4+ T cells measured by CFSE dilution. 
Dot plots are representative of 3 independent experi-
ments with 16 mice per group. (B) LNSCs and DCs were 
purified from CD11cDOG:WT or WT:WT chimeric mice, 
and ex vivo–cultured with TCR transgenic CD45.1 CD4+ 
T cells (OTII) for 3 d. OTII+ cells were harvested from and 
restimulated with anti-CD3/anti-CD28 for 3 additional d. 
Proliferation (percentage) of gated CD45.1+ CD4+ T cells 
measured by CFSE dilution. Dot plots are representative 
of 2 individual experiments with a pool of 20 mice/group.
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OVA-specific CD4+ T cell proliferation and survival were 
significantly impaired when T cells were cultured with LNSCs 
from CD11cDOG mice in which OVA is restricted to DCs. 
Interestingly, we observed an antigen-specific increase of T cell 
apoptosis which seems to be restricted to LECs and correlates 
with higher PD-L1 expression by LECs compared with FRCs 
and BECs. However, further investigations would be necessary 
to dissect LEC ability to induce T cell deletion. Altogether, our 
data demonstrated that LNSCs acquire pMHCII complexes 
from DCs and consequently impair self-antigen CD4+ T cell 
responses under steady-state conditions.
Our findings describe a novel mechanism, in which LNSCs 
maintain CD4+ T cell peripheral tolerance. Besides conven-
tional direct presentation of self-antigens to T cells, DCs can 
also transfer self-pMHCII complexes to LNSCs that in turn 
present these complexes to T cells and consequently induce 
dysfunctional self-antigen CD4+ T cell responses. Further stud-
ies are needed to decipher the relative contribution of DCs 
and LNSCs in maintaining T cell tolerance, and to determine 
whether endogenous expression of MHCII molecules by 
LNSCs similarly affects CD4+ T cell responses either upon 
steady-state or inflammatory conditions.
MATERIALS AND METHODS
Mice and treatments. C57BL/6 WT mice were either purchased from 
Charles River or bred in our specific pathogen-free facility. MHCII/  
(H2-Aa/; Köntgen et al., 1993), pI/, pIV/ (Waldburger et al., 2003), 
pIII+IV/ (LeibundGut-Landmann et al., 2004), Ciita/ (Laufer et al., 
1996), CD11cDOG (Hochweller et al., 2008), OT-II CD45.1+ (Barnden 
et al., 1998), K14-VEGFR3-Ig (provided by K. Alitalo, Institute of Biomedi-
cine, University of Helsinki, Helsinki, Finland; Mäkinen et al., 2001), I-Ab 
GFP (Boes et al., 2002; provided by A.M. Lennon-Dumenil, INSERM U932, 
Institut Curie, Paris, France), and Ifngr1/ (The Jackson Laboratory) mice 
have been previously described. These mouse strains are on a C57BL/6 back-
ground and were housed and maintained under SPF conditions. All animal 
husbandry and experiments were approved by and performed in accordance 
with guidelines from the Animal Research Committee of the University of 
Geneva. When indicated, IFN- (1 µg, both flanks) was injected subcutane-
ously. For some experiments, mice were irradiated with two consecutive doses 
of 300 cGy (Gammacell 40 Exactor).
LNSC isolation. LNSCs were obtained as previously described (Link et al., 
2007). In brief, total skin or skin-draining LNs from individual or 10–15 
pooled mice were cut into small pieces and digested in RPMI containing 
1 mg/ml Collagenase IV (Worthington Biochemical Corporation), 40 µg/ml 
DNase I (Roche), and 2% FBS. Undigested cells were further digested with 
1 mg/ml Collagenase d, and 40 µg/ml DNase I (Roche). The reaction was 
stopped by addition of 5 mM EDTA and 10% BSA. Samples were further 
disaggregated through a 70-µm cell strainer and blocked with anti-CD16/32 
antibody. Single cell suspensions were negatively selected using CD45 micro-
beads and magnetic bead column separation (Miltenyi Biotec).
Antibodies, flow cytometry, and cell sorting. Anti-gp38 (clone 8.1.1), 
anti-CD31 (clone 390), anti-CD11b (clone M1-70), anti-CD11c (clone 
N418), anti-CD45.1 (A20), anti-IAb (AF6.120.1), anti-CD80 (clone 16-
10A1), anti-CD86 (clone GL1), anti-PD-L1 (clone 10F.9G2), anti-CD63 
(clone NVG-2), and anti-F4/80 (clone BM8) mAbs were from BioLeg-
end. Anti-CD45 (clone 30F11), anti-CD103 (clone M290), anti-CD16/32 
FcyRIII (clone 2.4G2), anti-I-Ad/I-Ed (clone 2G9), anti–Annexin V mAbs were 
from BD. Anti-CD19 (1D3), anti-CD8 (clone 53–6.7), anti-CD40 (clone 
HM40-3), and anti-CD4 (GK1.5) were from eBioscience. Anti-CD3 and 
anti-CD28 were from Bio X Cell. For flow cytometry, enriched CD45neg cells 
express the specific antigen. The transfer of pMHC complexes 
from one cell to another has already been demonstrated with 
pMHCI transfer between DCs (Wakim and Bevan, 2011) and 
pMHCII from DCs to NK cells (Nakayama et al., 2011). Dif-
ferent mechanisms for intercellular protein transfer between 
immune cells have been described, including the uprooting of 
proteins from cell membranes, the transfer of protein ecto-
domains after proteolytic cleavage, the transfer of enclosed 
membrane bodies or vesicles, small membrane bridges which 
occur after intercellular membrane fusion, and finally mem-
brane nanotubules which may derive from membrane fusion 
or bridges (Davis, 2007). In vitro, transfer of MHCII to LNSCs 
is dramatically dampened when DCs and LNSCs were cul-
tured in separated compartments, suggesting that this process 
is mostly cell–cell contact–dependent. However, our data sug-
gest that DC-derived exosomes might also play a role. Mech-
anisms by which cells take up DC-derived exosomes are not 
yet well defined. Exosomes can either be adsorbed to the cell 
surface of the recipient cell nonspecifically or through active 
phagocyte or receptor-mediated endocytosis. In this regard, 
differential expression of adhesion molecules has been in-
volved in their target and uptake by DCs (Segura et al., 2007). 
Therefore, differential adhesion molecule expression on LECs, 
BECs, and FRCs (Malhotra et al., 2012) might lead to differ-
ent levels of exosome uptake. Whether exosomes actually play 
a role in pMHCII complex transfer from DCs to LNSCs in 
vivo remains to be determined. Indeed, MHCII transfer was 
considerably less efficient using exosomes compared with 
BM-DCs, suggesting that cell–cell contact dependent mecha-
nisms are mainly involved. This is a sound hypothesis, given 
the location of LNSCs along the DC migratory pathway, and 
requires further study.
Whether cultured alone or in the presence of DCs, LECs 
and FRCs remained CD11c negative and expressed the same 
low levels of co-stimulatory molecules, suggesting that the 
process of transfer from DCs to LNSCs is restricted to MHCII 
molecules, as already proposed for NK cells (Nakayama et al., 
2011). An alternative possibility is that DCs also transfer other 
molecules to LNSCs, which are rather actively internalized 
from the cell surface and MHCII molecules would be recy-
cled to the cell membrane.
LNSCs exhibit many features needed to induce T cell tol-
erance, including their localization in LNs allowing perma-
nent interactions with T cells, the absence of co-stimulatory 
molecules, and the presence of co-inhibitory molecules. 
A recent study demonstrated that one particular subset of 
CD45loCD11cintgp38negCD31neg cells in secondary lymphoid 
organs, the eTACs, induces cognate CD4+ T cell inactiva-
tion (Gardner et al., 2013). eTACs were described to originate 
from both radioresistant and radiosensitive origins, and to ex-
press low levels of CD11c and CD45. Here we provide con-
vincing evidence that radioresistant CD45neg LECs, BECs, 
and FRCs also impact CD4+ T cell responses. First, we con-
firmed published observations that proliferation of CD4+  
T cells exposed to LECs, BECs, and FRCs was inhibited 
independently of antigen presentation by LNSCs. Second, 
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using CD4+ T cell depletion kit and the MACS system (Miltenyi Biotec). 
Naive CFSE-labeled OT-II cells (5 × 104) were co-cultured with sorted 
5 × 104 LNSC or DC for 3 d. After 3 d, OT-II cells were harvested and cul-
ture in an anti-CD3/anti-CD28 (1 µg/ml) precoated plates for an additional 
3 d. Cells were stained for surface markers and proliferation was measured by 
CFSE dilution in a FACSCalibur (BD).
CH model. A 1:1 mixture of acetone and dibutyl phthalate was applied 
epicutaneously in the back skin of mice (Vigl et al., 2011). Draining LNs were 
excised and analyzed after 24 or 48 h.
RNA isolation and quantitative RT-PCR. Total RNA was prepared with 
TRIZOL Reagent (Invitrogen) from sorted LNSCs. cDNA was synthesized 
with random hexamers and Superscript II reverse transcription (Invitrogen). 
PCRs for CIITA promoters were performed with the iCycler iQ Real-Time 
PCR detection System and iQ SYBR green super mix (Bio-Rad Labora-
tories). Results were quantified with a standard curve generated with se-
rial dilutions of a reference cDNA preparation. Primer sequences: CIITA pI 
forward, 5-CAGGGACCATGGAGACCATAGT-3 and reverse, 5-CAG-
GTAGCTGCCCTCTGGAG-3; CIITA pIII forward, 5-GGTTCCTG-
GCCCTTCTGG-3 and reverse, 5-ATCCATGGTGGCACACAGACT-3; 
and CIITA pIV forward, 5-CAGCACTCAGAAGCACGGG-3 and reverse, 
5-ATCCATGGTGGCACACAGACT-3. Results were normalized with 
GAPDH mRNA expression and quantified with a standard curve generated 
with serial dilutions of a reference thymic cDNA preparation. OVA mRNA 
levels were measured by TaqMan PCR in an ABI 7700 PCR machine (Azco 
Biotech). Primer sequences: OVA forward, 5-CCATTTGCCAGTGGGA-
CAAT-3, reverse, 5-TCAAGCTGCTCAAGGCCTG-3, and Tg probe, 
5-(FAM)CATGTTGGTGCTGTTGCCTGATGAAGTC(TAMRA)-3; 
and internal control forward, 5-CACGTGGGCTCCAGCATT-3, reverse, 
5-TCACCAGTCATTTCTGCCTTTG-3, and probe, 5-(JOE NHS 
Ester)CCAATGGTCGGGCACTGCTCAA(BHQ1)-3.
Statistical analysis. Statistical significance was assessed by the two-tailed 
unpaired Student’s t test and ANOVA using Prism 5.0 software (Graph-
Pad Software).
Online supplemental material. Fig. S1 shows flow cytometry dot plots 
describing LNSC subpopulations. Fig. S2 shows differential regulation of the 
gene encoding the MHC CIITA in indicated cell subtypes. Fig. S3 depicts 
the gating strategy used for the FACS sorting of different DC subsets in LN 
for Fig. 3 F. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20132000/DC1.
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